Fig. 5

GCNT3 inhibition enhanced Gem/Txl standard therapy efficacy in orthotopic syngeneic PDAC mouse model. a Plot showing individual tumor growth curves of KPC06 tumor bearing mice (n = 5) randomly assigned to receive saline (CTR), standard therapy (Gem/Txl), talniflumate (TALN) and talniflumate-Gem/Txl combination treatment (COMB). b Barplot showing tumor growth grouped by treatment. Wilcoxon signed-rank test was used to compare differences between treatments. *** = Pvalue < 0.01, * = Pvalue < 0.05, NS = not significant. c Plot showing the overall survival of KPC mice divided according each experimental condition